Clinical trial

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With…

NCT00405951 · Gemin X, Industry · Completed

Key facts

NCT number NCT00405951
Title Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer
Official title A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered Every 3 Weeks in Combination With Docetaxel to Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor Gemin X, Industry
Status Completed
Phase Phase 1/Phase 2
Study type Interventional
Conditions Lung Cancer
Intervention type Drug
Interventions Obatoclax mesylate 250 ml, Docetaxel
Enrollment 47
Start date Oct 1, 2006
Primary completion Nov 1, 2008
Completion Sep 1, 2009
First posted Dec 4, 2006
Last update posted Jul 21, 2016
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies